Cash constraints are forcing Corvus Pharmaceuticals to clip the wings of its lead candidate. Rather than advance on multiple fronts, the biotech is focusing on cancers including T-cell lymphoma and ...
Management outlined plans to initiate the Phase II trial for soquelitinib in atopic dermatitis before year-end, with enrollment of approximately 200 patients. The treatment period is set for 12 weeks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results